Linda Duska headshot
LD

Linda Duska

Professor
Unit: School of Medicine
Department: Department of Obstetrics and Gynecology
Office location and address
Emily Couric Clinical Cancer Center
81 Hospital Dr
Charlottesville, Virginia 22903
Education
New York University School of Medicine, 1991, MD
Residency, Obstetrics and Gynecology, Johns Hopkins Hospital
Fellowship, Gynecologic Oncology, Massachusetts General Hospital
Consultant for Merck - MK-3475 A18/ENGOT cx11 Scientific Advisory Committee (SAC)
Source: Merck Sharp & Dohme Corp.
March 26, 2020 – March 25, 2025
Phase II Trial of Niraparib in Combination with Dostarlimab in Patients with Recurrent or Progressive Cervix Cancer (STAR)
Source: University Of Oklahoma
February 16, 2021 – February 15, 2024
MD-OBGY-GYN - Duska - NRG GY021
Source: NRG Oncology Foundation, Inc.
December 15, 2020 – December 14, 2023
HSR200269 - Duska - EP0057-201
Source: Psi Pharma Support America Inc.
December 07, 2020 – December 06, 2023
Endometrial Cancer Molecularly Targeted Therapy Consortium
Source: Duke University
July 29, 2021 – July 01, 2023
MD-OBGY Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cervical Cancer
Source: Merck Sharp & Dohme Corp.
December 18, 2015 – June 30, 2023
A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors
Source: Clinipace, Inc.
April 30, 2020 – April 29, 2023
Arcus Biosciences Cervical Cancer Advisory Board
Source: Arcus Biosciences, Inc.
March 21, 2021 – March 20, 2023
A PROSPECTIVE OBSERVATIONAL COHORT STUDY TO DEVELOP A PREDICTIVE MODEL OF TAXANE-INDUCED PERIPHERAL NEUROPATHY IN CANCER PATIENTS
Source: ECOG-ACRIN Cancer Research Group
March 10, 2020 – March 09, 2023
A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer
Source: Johns Hopkins University, The
March 02, 2021 – February 28, 2023
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With M3814 in Platinum-Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer
Source: Johns Hopkins University, The
April 13, 2020 – February 28, 2023
Phase 2 Study of VX-970 (NSC# 780162) in Combination with gemcitabine versus gemcitabine alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer
Source: Johns Hopkins University, The
September 01, 2017 – February 28, 2023
A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer
Source: Johns Hopkins University, The
August 20, 2020 – February 28, 2023
Consulting Agreement with MERCK
Source: Merck Sharp & Dohme Corp.
September 28, 2020 – December 31, 2022
A Dose Escalation and Expansion Study of TRX518 in Combination with Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Source: CE3, Inc.
September 18, 2019 – September 17, 2022
Consulting Agreement | Eisai Virtual US Medical Affairs EC Advisory Board
Source: Eisai, Inc.
August 18, 2021 – August 17, 2022
MERCK US Gynecologic Cancer Advisory Board Participation
Source: Merck & Co Inc
October 22, 2020 – August 01, 2022
MD-OBGY Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serious Epithelial Ovari
Source: The GOG Foundation
December 01, 2015 – June 30, 2022
Agenus/GOG-3028
Source: LabCorp Drug Development, Inc.
June 18, 2019 – June 18, 2022
GYN-COE TDAN Protocol and Collaborative Research with University of Virginia (UVA) - TDAN 2021
Source: The Henry M. Jackson Foundation
April 27, 2021 – April 26, 2022
Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
Source: Seattle Genetics, Inc.
April 26, 2019 – April 25, 2022
ASCO-ACCC Pilot Project
Source: American Society of Clinical Oncology Cancer Found
August 06, 2021 – March 31, 2022
GYN-COE TDAN Protocol and Collaborative Research with University of Virginia (UVA) - Supplement
Source: The Henry M. Jackson Foundation
March 01, 2019 – February 28, 2022
Eisai Advisory Board Consulting Agreement
Source: Eisai, Inc.
January 27, 2021 – January 26, 2022
Agenus MD Consulting Agreement
Source: Agenus Inc.
November 19, 2020 – November 19, 2021
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer
Source: Leap Therapeutics, Inc.
August 08, 2018 – August 07, 2021
Consulting professional services for AbbVie¿s 2020 Oncology Veliparib Advisory Board
Source: AbbVie Inc.
May 07, 2020 – May 06, 2021
NRG-GY016 - A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Source: NRG Oncology Foundation, Inc.
October 16, 2018 – February 28, 2021
GYN-COE TDAN Protocol and Collaborative Research with University of Virginia (UVA)
Source: The Henry M. Jackson Foundation
March 01, 2017 – February 28, 2021
MD-OBGY A Phase II randomized trial of gemcitabine vs gemcitabine and pazopanib in ovarian cancer
Source: GlaxoSmithkline Beecham Pharmaceuticals
July 12, 2012 – January 01, 2021
MD-OBGY A Phase II randomized trial of gemcitabine vs gemcitabine and pazopanib in ovarian cancer
Source: Novartis Pharmaceuticals Corporation
September 16, 2016 – January 01, 2021
MD-OBGY-A Phase II Study of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer
Source: Merck Sharp & Dohme Corp.
June 14, 2016 – March 30, 2020
MD-OBGY CORAIL Trial - Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platnum-resistant Ovarian Cancer (CORAIL Trial)
Source: Syneos Health, LLC
June 30, 2015 – March 17, 2020
MD-OBGY Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix
Source: Syneos Health, LLC
September 15, 2015 – February 28, 2019
AS-ECON IPA agreement for Federico Ciliberto for Fall 2016
Source: U.S. Department Of Justice
August 25, 2016 – January 09, 2017
Randomized Phase 2 Study of MLN8237
Source: Millennium Pharmaceuticals, Inc.
March 20, 2012 – December 31, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
A Study to Evaluate the Safety & Efficacy of NKTR-102 (PEG-Irinotecan) when given on a Q14 or a Q21 day schedule in Patients with Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian
Source: Nektar Therapeutics
June 29, 2009 – June 28, 2013
  • 2011-2018 Best Doctors in America® List
  • 2015 One of America's Top Cancer Doctors, Newsweek®